What "strong growth" ?
The testing services business is yet to perform. Growth is sluggish and not what was projected when it IPO'd.
The directors then decide to acquire revenue by buying a business in the UK that doesn't make a profit and to do that they do a heavily dilutive cap raising at 23 cents which was a 30% discount to the then prevailing share price.
Shareholders have been done over. The next quarterly is likely to show a continuation of big cash burn.
Ann: Completion of Autoimmune Program with Ginkgo Bioworks, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $47.38M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 30000 | 9.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.5¢ | 114482 | 1 |
View Market Depth
| Last trade - 09.59am 30/07/2025 (20 minute delay) ? |
| MAP (ASX) Chart |
Day chart unavailable